#USA #Minneapolis #CFO Appointment #VentureMed Group #Bruce Fiedler

VentureMed Group Welcomes Bruce Fiedler as Chief Financial Officer

Introduction

On February 11, 2026, VentureMed Group, Inc., a pioneering medical device company based in Minneapolis, made headlines with the appointment of Bruce Fiedler as its Chief Financial Officer (CFO). The company is renowned for its advancement in vessel preparation and access management technologies, particularly for treating arteriovenous fistulas and peripheral vascular diseases. Fiedler’s extensive experience in finance, especially within the healthcare and technology sectors, brings a wealth of knowledge to the team.

The Role of CFO

In his new role as CFO, Fiedler will oversee all financial activities at VentureMed Group. This encompasses areas such as strategic planning, financial reporting, capital allocation, and maintaining investor relations. His leadership is expected to be crucial as the company aims for continuous growth, advancing innovative vascular solutions that address the clinical needs of healthcare practitioners and patients around the globe.

Leadership Perspective

Denis Harrington, the President and CEO of VentureMed Group, expressed enthusiasm over Fiedler's appointment, stating, "We are pleased to welcome Bruce to the VentureMed Group leadership team. His financial expertise and experience in scaling operations within the medical technology industry will be invaluable as we enter our next phase of growth." This statement highlights the importance of Fiedler’s skills in enhancing the company’s financial foundation, positioning it for long-term success.

Bruce Fiedler's Background

Fiedler's career includes a long tenure at Boston Scientific, where he excelled in various senior finance roles. Most recently, he served as Vice President and Global Controller for the Neuromodulation Division, where he supervised financial planning and control for a major global business segment. With a proven history of operational excellence and financial discipline, Fiedler is well-equipped to contribute to VentureMed Group’s mission.

Before joining Boston Scientific, Fiedler garnered a reputation for fostering collaboration across departments and driving innovative solutions that consistently improved business outcomes. His extensive background in the healthcare sector aligns perfectly with VentureMed's commitment to innovation and excellence.

Commitment to Innovation

In his own words, Fiedler expressed excitement about joining the organization during this transformative phase. He remarked, "The company's mission to address unmet clinical needs through innovative vascular solutions is compelling, and I look forward to working with the team to drive growth and meaningful impact for patients and physicians." This reflects a shared commitment to enhancing patient care through cutting-edge technology and financial stewardship.

About VentureMed Group

VentureMed Group is dedicated to advancing endovascular solutions, particularly for arteriovenous (AV) access and peripheral vascular disease interventions. The company’s flagship product is the FLEX Vessel Prep™ System, which has received both FDA 510(k) clearance and CE Mark approval. This innovative device optimizes vessel preparation using proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology. Unlike traditional methods that rely on static pressure, KEMIC employs controlled motion to create precise micro-incisions, leading to improved patient outcomes.

Conclusion

With Bruce Fiedler at the financial helm, VentureMed Group is poised for significant growth and innovation in the medical device industry. His extensive experience and strategic leadership will be pivotal in navigating the complexities of the healthcare landscape, ultimately benefiting patients and practitioners alike. The appointment of Fiedler not only reinforces VentureMed Group's commitment to excellence but also its focus on enhancing medical technologies critical to patient care.

For additional information, visit VentureMed Group.